Varian wins Taiwan FDA approval for new cancer treatment system, Halcyon.
M2 PHARMA-January 9, 2018-Varian wins Taiwan FDA approval for new cancer treatment system, Halcyon
(C)2018 M2 COMMUNICATIONS
Medical devices company Varian (NYSE:VAR) reported on Monday the receipt of approval from the Taiwan FDA for its new cancer treatment system, Halcyon.
This approval allows the company to market Halcyon in Taiwan as well as further expands its global availability and high-quality, cost-effective cancer treatments.
An advanced cancer treatment system with a human-centred and user-friendly design, Halcyon is engineered to revolutionise clinical workflow, accelerate installation timeframes, expedite commissioning, simplify training and automate treatment, enhance most aspects of image-guided volumetric intensity modulated radiotherapy (IMRT) and offer advanced treatments for lung, esophagus, brain, head & neck, as well as many other forms of cancer.
Halcyon's design has shown to enhance patient comfort and increase the treatment efficiency. With the streamlined workflow, the system only requires nine steps from the start to the end of treatment compared to up to more than 30 steps with older technologies, added the company.
In conjunction, Halcyon has received FDA 510(k) clearance in the US, CE mark in Europe, Shonin approval in Japan and ANVISA registration in Brazil since its launch in May 2017.
((Comments on this story may be sent to firstname.lastname@example.org))
|Printer friendly Cite/link Email Feedback|
|Date:||Jan 9, 2018|
|Previous Article:||Sanofi and Regeneron to expand investment in development of cemiplimab and dupilumab.|
|Next Article:||Clearbridge BioMedics awarded US FDA Class I Medical Device listing for ClearCell FX1 system.|